DNA damage induces phosphorylation of the amino terminus of p53

Genes and Development

Volumn 11, Issue 24, 1997, Pages 3471-3481

  Siliciano, Janet D ^a   Canman, Christine E ^a   Taya, Yoichi ^b   Sakaguchi, Kazuyasu ^c   Appella, Ettore ^c   Kastan, Michael B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

ATM; Genotoxic stress; p53; Phosphorylation

Indexed keywords

DNA; PHOSPHOPEPTIDE; PROTEIN P53; RECOMBINANT PROTEIN; SERINE;

AMINO TERMINAL SEQUENCE; ARTICLE; ATAXIA TELANGIECTASIA; CONTROLLED STUDY; DNA DAMAGE; GENE MUTATION; GENE TARGETING; GENOTOXICITY; HUMAN; HUMAN CELL; IONIZING RADIATION; LYMPHOBLAST; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION;

ATAXIA; ATAXIA TELANGIECTASIA;

EID: 0031435944     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.11.24.3471     Document Type: Article

References (56)

1. Adler, V., M.R. Pincus, T. Minamoto, S.Y. Fuchs, M.J. Bluth, P.W. Brandt-Rauf, F.K. Friedman, R.C. Robinson, J.M. Chen, X.W. Wang, C.C. Harris, and Z. Ronai. 1997. Conformation-dependent phosphorylation of p53. Proc. Natl. Acad. Sci. 94: 1686-1691.
2. Baudier, J., C. Delphin, D. Grunwald, S. Khochbin, and J.J. Lawrence. 1992. Characterization of the tumor suppressor protein p53 as a protein kinase C substrate and a S100b-binding protein. Proc. Natl. Acad. Sci. 89: 11627-11631.
3. Bischoff, J.R., P.N. Friedman, D.R. Marshak, C. Prives, and D. Beach. 1990. Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc. Natl. Acad. Sci. 87: 4766-4770.
4. Bogue, M.A., C. Zhu, E. Aguilar-Cordova, L.A. Donehower, and D.B. Roth. 1996. p53 is required for both radiation-induced differentiation and rescue of V(D)J rearrangement in seid mouse thymocytes. Genes &. Dev. 10: 553-565.
5. Boyle, W.J., P. van der Geer, and T. Hunter. 1991. Phosphopeptide mapping and phosphoamino acid analysis by two-dimensional separation on thin-layer cellulose plates. Methods Enzymol. 201: 110-149.
6. Canman, C.E., A.C. Wolff, C. Chen, A.J. Fornace, and M.B. Kastan. 1994. The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia. Cancer Res. 54: 5054-5058.
7. Canman, C.E., T. Gilmer, S. Coutts, and M.B. Kastan. 1995. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes & Dev. 9: 600-611.
8. Chen, J., V. Marechal, and A.J. Levine. 1993. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13: 4107-4114.
9. Danska, J.S., D.P. Holland, S. Mariathasan, K.M. Williams, and C.J. Guidos. 1996. Biochemical and genetic defects in the DNA-dependent protein kinase in murine seid lymphocytes. Mol. Cell. Biol. 16: 5507-5517.
10. Derijard, B., M. Hibi, I.H. Wu, T. Barrett, B. Su, T. Deng, M. Karin, and R.J. Davis. 1994. JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76: 1025-1037.
11. El-Deiry, W.S., T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
12. Farmer, G., J. Colgan, Y. Nakatani, J.L. Manley, and C. Prives. 1996. Functional interaction between p53, the TATA-binding protein (TBP), and TBP-associated factors in vivo. Mol. Cell. Biol. 16: 4295-4304.
13. Fiscella, M., S.J. Ullrich, N. Zambrano, M.T. Shields, D. Lin, S.P. Lees-Miller, C.W. Anderson, W.E. Mercer, and E. Appella. 1993. Mutation of the serine-15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression. Oncogene 8: 1519-1528.
14. Gottlieb, T.M. and M. Oren. 1995. p53 in growth control and neoplasia. Biochim. Biophys. Acta 1287: 77-102.
15. Graeber, T.G., J.F. Peterson, M. Tsai, K. Monica, A.J. Fornace Jr., and A.J. Giaccia. 1994. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol. Cell. Biol. 14: 6264-6277.
16. Guidos, C.J., C.J. Williams, I. Grandal, G. Knowles, and M.T.F. Huang. 1996. V(D)J recombination activates a p53-dependent DNA damage checkpoint in scid lymphocyte precursors. Genes & Dev. 10: 2038-2054.
17. Hall, S.R., L.E. Campbell, and D.W. Meek. 1996. Phosphorylation of p53 at the casein kinase II site selectively regulates p53-dependent transcriptional repression but not transactivation. Nucleic Acids Res. 24: 1119-1126.
18. Hartwell, L.H. and M.B. Kastan. 1994. Cell cycle control and cancer. Science 266: 1821-1828.
19. Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299.
20. Huang, L., K.C. Clarkin, and G.M. Wahl. 1996. p53-dependent cell cycle arrests are preserved in DNA-activated protein kinase-deficient mouse fibroblasts. Cancer Res. 56: 2940-2944.
21. Hupp, T.R., D.W. Meek, C.A. Midgley, and D.P. Lane. 1992. Regulation of the specific DNA binding function of p53. Cell 71: 875-886.
22. Kastan, M.B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R.W. Craig. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51: 6304-6311.
23. Kastan, M.B., Q. Zhan, W.S. El-Deiry, F. Carrier, T. Jacks, W.V. Walsh, B.S. Plunkett, B. Vogelstein, and A.J. Fomace Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587-597.
24. Khanna, K.K. and M.F. Lavin. 1993. Ionizing radiation and UV induction of p53 protein by different pathways in ataxia-telangiectasia cells. Oncogene 8: 3307-3312.
25. King, D.S., C.G. Fields, and G.B. Fields. 1990. A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis. Int. J. Peptide Protein Res. 36: 255-266.
26. Kitagawa, M., H. Higashi, H.K. Jung, I. Suzuki-Takahashi, M. Ikeda, K. Tamai, J. Kato, K. Segawa, E. Yoshida, S. Nishimura, and Y. Taya. 1996. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J. 15: 7060-7069.
27. Ko, L.J. and C. Prives. 1996. p53: Puzzle and paradigm. Genes & Dev. 10: 1054-1072.
28. Kubbutat, M.H.G., S.N. Jones, and K.H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387: 299-303.
29. Lavin, M.F., K.K. Khanna, H. Beamish, B. Teale, K. Hobson, and D. Watters. 1994. Defect in radiation signal transduction in ataxia-telangiectasia. Int. J. Radiat. Biol. 66: S151-S156.
30. Lees-Miller, S.P., K. Sakaguchi, S.J. Ullrich, E. Appella, and C.W. Anderson. 1992. Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol. Cell. Biol. 12: 5041-5049.
31. 1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes & Dev. 10: 934-947.
32. 7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro. Mol. Cell. Biol. 17: 5923-5934.
33. Maki, C.G., J.M. Huibregtse, and P.M. Howley. 1996. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res. 56: 2649-2654.
34. Maltzman, W. and L. Czyzyk. 1984. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4: 1689-1694.
35. 2 terminus of p53 facilitates transactivation. Cancer Res. 55: 2410-2417.
36. Milne, D.M., R.H. Palmer, D.G. Campbell, and D.W. Meek. 1992. Phosphorylation of the p53 tumour-suppressor protein at three N-terminal sites by a novel casein kinase I-like enzyme. Oncogene 7: 1361-1369.
37. Milne, D.M., D.G. Campbell, F.B. Caudwell, and D.W. Meek. 1994. Phosphorylation of the tumor suppressor protein p53 by mitogen-activated protein kinases. J. Biol. Chem. 269: 9253-9260.
38. Milne, D.M., L.E. Campbell, D.G. Campbell, and D.W. Meek. 1995. p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1. J. Biol Chem. 270: 5511-5518.
39. Momand, J., G.P. Zambetti, D.C. Olson, D.L. George, and A.J. Levine. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245.
40. Morgan, S.E. and M.B. Kastan. 1997. p53 and ATM: Cell cycle, cell death and cancer. Adv. Cancer Res. 71: 1-25.
41. Nacht, M., A. Strasser, Y.R. Chan, A.W. Harris, M. Schlissel, R.T. Bronson, and T. Jacks. 1996. Mutations in the p53 and SCID genes cooperate in tumorigenesis. Genes & Dev. 10: 2055-2066.
42. Nelson, W.G. and M.B. Kastan. 1994. DNA strand breaks: The DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell Biol. 14: 1815-1823.
43. Picksley, S.M., B. Vojtesek, A. Sparks, and D.P. Lane. 1994. Immunochemical analysis of the interaction of p53 with MDM2; fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 9: 2523-2529.
44. Rathmell, W.K., W.K. Kaufmann, J.C. Hurt, L.L. Byrd, and G. Chu. 1997. DNA-dependent protein kinase is not required for accumulation of p53 or cell cycle arrest after DNA damage. Cancer Res. 57: 68-74.
45. Rosette, C. and M. Karin. 1996. Ultraviolet light and osmotic stress: Activation of the JNK cascade through multiple growth factor and cytokine receptors. Science 274: 1194-1197.
46. Santos, J.A., E. Logarinho, C. Tapia, C.C. Allende, J.E. Allende, and C.E. Sunkel. 1996. The casein kinase 1α gene of Drosophila melanogaster is developmentally regulated and the kinase activity of the protein induced by DNA damage. J. Cell Sci. 109: 1847-1856.
47. Savitsky, K., A. Bar-Shira, S. Gilad, G. Rotman, Y. Ziv, L. Vanagaite, D.A. Tagle, S. Smith, T. Uziel, S. Sfez, M. Ashkenazi, I. Pecker, M. Frydman, R. Harnik, S.R. Patanjali, A. Simmons, G.A. Clines, A. Sartiel, R.A. Gatti, L. Chessa, O. Sanal, M.F. Lavin, N.G.J. Jaspers, A.M.R. Taylor, C.F. Arlett, T. Miki, S.M. Weissman, M. Lovett, F.S. Collins, and Y. Shiloh. 1995. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268: 1749-1753.
48. Shieh, S.Y. M. Ikeda, Y. Taya, and C. Prives. 1997. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334.
49. Shiloh, Y. and G. Rotman. 1996. Ataxia-telangiectasia and the ATM gene - linking neurodegeneration, immunodeficiency, and cancer to cell cycle checkpoints. J. Clin. Immunol. 16: 254-260.
50. Takenaka, I., F. Morin, B.R. Seizinger, and N. Kley. 1995. Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases. J. Biol. Chem. 270: 5405-5411.
51. II60. Science 267: 100-104.
52. Wakamiya, T., K. Saruta, J. Yasuoka, and S. Kusumoto. 1994. An efficient procedure for solid-phase synthesis of phosphopeptides by the Fmoc strategy. Chem. Lett. 1099-1102.
53. Wang, Y. and C. Prives. 1995. Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature 376: 88-91.
54. Xu, Y. and D. Baltimore. 1996, Dual roles of ATM in the cellular response to radiation and in cell growth control. Genes & Dev. 10: 2401-2410.
55. Zakian, V.A. 1995. ATM-related genes: What do they tell us about functions of the human gene? Cell 82: 685-687.
56. Zauberman, A., Y. Barak, N. Ragimov, N. Levy, and M. Oren. 1993. Sequence-specific DNA binding by p53: Identification of target sites and lack of binding to p53-MDM2 complexes. EMBO J. 12: 2799-2808.